Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor

We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumou...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Donald, Tan, Min Han, Khor, Damian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717/
https://www.ncbi.nlm.nih.gov/pubmed/34511423
http://dx.doi.org/10.1136/bcr-2021-244271
_version_ 1783752402042617856
author Poon, Donald
Tan, Min Han
Khor, Damian
author_facet Poon, Donald
Tan, Min Han
Khor, Damian
author_sort Poon, Donald
collection PubMed
description We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumour somatic mutation profiling. There is ongoing complete response at 10 months after initiation of erdafitinib. Transient central serous retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events encountered.
format Online
Article
Text
id pubmed-8438717
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84387172021-09-24 Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor Poon, Donald Tan, Min Han Khor, Damian BMJ Case Rep Case Report We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumour somatic mutation profiling. There is ongoing complete response at 10 months after initiation of erdafitinib. Transient central serous retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events encountered. BMJ Publishing Group 2021-09-12 /pmc/articles/PMC8438717/ /pubmed/34511423 http://dx.doi.org/10.1136/bcr-2021-244271 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Poon, Donald
Tan, Min Han
Khor, Damian
Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title_full Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title_fullStr Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title_full_unstemmed Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title_short Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
title_sort stage 4 pancreatic adenocarcinoma harbouring an fgfr2-tacc2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717/
https://www.ncbi.nlm.nih.gov/pubmed/34511423
http://dx.doi.org/10.1136/bcr-2021-244271
work_keys_str_mv AT poondonald stage4pancreaticadenocarcinomaharbouringanfgfr2tacc2fusionmutationwithcompleteresponsetoerdafitinibapanfibroblasticgrowthfactorreceptorinhibitor
AT tanminhan stage4pancreaticadenocarcinomaharbouringanfgfr2tacc2fusionmutationwithcompleteresponsetoerdafitinibapanfibroblasticgrowthfactorreceptorinhibitor
AT khordamian stage4pancreaticadenocarcinomaharbouringanfgfr2tacc2fusionmutationwithcompleteresponsetoerdafitinibapanfibroblasticgrowthfactorreceptorinhibitor

Ejemplares similares